Mammalian target of rapamycin inhibitor-associated stomatitis - Wikidata - awgldk - TriplyDB

Mammalian target of rapamycin inhibitor-associated stomatitis

Mammalian target of rapamycin inhibitor-associated stomatitis

http://www.wikidata.org/entity/Q26825301

about

Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice Oral Mucositis Induced By Anticancer Therapies Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours.Adverse event management of oral mucositis in patients with breast cancer Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy.Rapamycin Eye Drops Suppress Lacrimal Gland Inflammation In a Murine Model of Sjögren's Syndrome.S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.Risk factors for stomatitis in patients with lymphangioleiomyomatosis during treatment with sirolimus: A multicenter investigator-initiated prospective study.Safety of mTOR inhibitors in adult solid organ transplantation.Mammalian-target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D-MDS).Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis.Current Trends in Management of Oral Mucositis in Cancer Treatment Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors.A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.Everolimus-associated stomatitis in a patient who had renal transplant.A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France.On the pathogenesis of mTOR inhibitor-associated stomatitis (mIAS)-studies using an organotypic model of the oral mucosa.Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up.Topical Application of a Galenical Formulation for the Management of Everolimus-Induced Mucositis in Patients with Metastatic Cancer: a Retrospective Study.Bullous pemphigoid induced by m-TOR inhibitors in renal transplant recipients.A randomized controlled trial to establish effects of short-term rapamycin treatment in 24 middle-aged companion dogs.

P2860

Q24186965-DDE2CB13-C373-444F-8D69-0AE002117BB8 Q24187456-44611A55-06D9-4F21-8FEF-3169A329107B Q24188283-D9ACD942-E030-4E3B-B937-C24D7CB696B0 Q26743390-D681D303-AB4B-47D3-8D0C-AB53F5CCF708 Q26777493-2BC554F0-3128-49E3-9F01-FF2CEA58C0C1 Q33424649-8B50D207-267E-4EE3-9420-395C2EDF83C9 Q34403510-8C4A57A0-7A1D-4640-A863-003FAA89E132 Q36627189-C2A35DCC-7141-44C0-AD75-DEFCBEF1A88A Q37610134-759CAAB6-3A3F-4A5C-8F50-2FD9A295877B Q38619215-DCECF67B-D7C2-4FC6-91C6-878C736B1E2A Q38655823-ACA346E3-BAD7-44E5-9904-EB772ED2B75D Q38669190-44144ABF-B0E5-4C3E-88AE-91FA8953CDBA Q40550970-63CD4E6D-870C-454C-B662-2E4FEBFEB2DA Q46882688-2F06F4B7-EAC0-4B7C-B93C-953B85CD40F5 Q47104925-B634ABF4-CBEE-49FE-BA0A-A3E7D877D479 Q47404146-2344C1AC-8A7D-4E7E-B4DE-454DBAAAB77F Q47572918-35A26001-B5A4-4DCF-9525-C283085FE209 Q47582481-0A8D8E0E-AC0F-49A8-BECC-1297DC9FA434 Q48261908-26854C20-339B-4EEB-92EB-ED74DCB15709 Q50898788-4330BF43-41DB-4A96-99D0-E3BC7A5B6258 Q51038341-29F94615-FF2C-4265-AD93-F3CCA2E18DB0 Q51272851-579B38E2-DD0D-45B1-B295-ABDE9E6741F8 Q53440587-AF16CEF7-29D2-4498-AAE5-65D88AA7AA38 Q54858266-1737E514-BE86-4F8D-A3ED-C943B20862AF Q55071511-3FDAC8FB-CE8E-437B-8E48-34532C774291 Q55174539-51896B95-08D1-41CA-94FF-3477936D4899

P2860

Mammalian target of rapamycin inhibitor-associated stomatitis

http://www.wikidata.org/entity/Q26825301

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Mammalian target of rapamycin inhibitor-associated stomatitis

@ast

Mammalian target of rapamycin inhibitor-associated stomatitis

@en

Mammalian target of rapamycin inhibitor-associated stomatitis

@nl

type

label

Mammalian target of rapamycin inhibitor-associated stomatitis

@ast

Mammalian target of rapamycin inhibitor-associated stomatitis

@en

Mammalian target of rapamycin inhibitor-associated stomatitis

@nl

prefLabel

Mammalian target of rapamycin inhibitor-associated stomatitis

@ast

Mammalian target of rapamycin inhibitor-associated stomatitis

@en

Mammalian target of rapamycin inhibitor-associated stomatitis

@nl

P1433

Q26825301-506AD120-7A18-4382-8382-EC36CAB47ACA

P1476

Q26825301-05BF136F-A5B0-403B-A86D-BFED1640A244

P2093

Q26825301-1BD982D1-0E35-4ABB-B299-D79AA222D912

Q26825301-1DA8550F-78BD-410D-994B-76E2A31A92E2

Q26825301-2F58434E-0195-4D1A-A4A2-EE3927288398

Q26825301-3C944E74-7CE3-4D46-9AE0-84AC9FA8C447

Q26825301-48561C40-28A5-4D49-9AB9-E9BD4D76CCCA

Q26825301-522CE30F-B2B0-470B-A02B-B9970F8FFBE4

Q26825301-87801CF0-36F9-4BC9-8C8D-C73BDD110B5B

Q26825301-9FE391B3-97AB-46B8-A9C1-B9F61E75851D

Q26825301-ACD6527B-06F7-4CE9-AA2E-D2AFA7BD5035

Q26825301-DE6DC355-B7C4-4AB8-92F2-CE3FB2468A02

P2860

Q26825301-09466049-748F-4F24-A819-90569A557D9C

Q26825301-0E8C30C4-C5C3-4272-B51C-F38C11C0BA96

Q26825301-0F3EC8EE-D74C-4F81-9DFF-0721D1E79B89

Q26825301-1083FBC0-4C90-449C-AAD4-053D2C35B3D9

Q26825301-1789E296-70C0-4E7E-8015-8040B6361409

Q26825301-1C1C4F93-18A9-4419-94D1-F166F86A8782

Q26825301-2687E132-E05B-4762-9809-EF8E57AA589B

Q26825301-2EBDA269-CBD7-422A-8D79-EDD9623EC08C

Q26825301-3C052E52-3A49-49D9-9672-B556B7A4D9D3

Q26825301-4194F0D5-2CBF-46DA-8BCB-7F191D3043A3

P304

Q26825301-B6E794D2-3E0F-4B65-A930-97D21E398074

P31

Q26825301-F77399FF-4026-4191-AA3C-06EEE71260D5

P3181

Q26825301-EDEF490E-5FF7-421E-80BC-C8D4F3A88573

P356

Q26825301-A34C5DE0-96E6-4216-91E9-F054E77B3097

P407

Q26825301-382E040C-0433-4977-A52B-82E6E5B5927B

P433

Q26825301-E406A12F-6BE3-4730-98D9-EF7DB96B2216

P478

Q26825301-C18ED8C7-CEB6-4E37-A143-56EA10E3DF87

P577

Q26825301-57C59CF9-0834-4E65-ACD9-4195C50EAA06

P5875

Q26825301-34965DC5-2584-474C-AA34-79DC04A31393

P698

Q26825301-D7C2B943-52A8-42F6-BAA2-9C45E45A57C4

P3181

P356

P1433

Future Oncology

P1476

Mammalian target of rapamycin inhibitor-associated stomatitis

@en

P2093

Anniek BP Arends

http://www.w3.org/2001/XMLSchema#string

Christine B Boers-Doets

http://www.w3.org/2001/XMLSchema#string

Diede R Wiersma

http://www.w3.org/2001/XMLSchema#string

Hans Gelderblom

http://www.w3.org/2001/XMLSchema#string

Joel B Epstein

http://www.w3.org/2001/XMLSchema#string

Judith E Raber-Durlacher

http://www.w3.org/2001/XMLSchema#string

Nathaniel S Treister

http://www.w3.org/2001/XMLSchema#string

Nielka P van Erp

http://www.w3.org/2001/XMLSchema#string

Rajesh V Lalla

http://www.w3.org/2001/XMLSchema#string

Richard M Logan

http://www.w3.org/2001/XMLSchema#string

P2860

Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

Current development of mTOR inhibitors as anticancer agents

The TOR pathway: a target for cancer therapy

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.

Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy. Mucositis Study Group.

A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea.

Clinical practice. Aphthous ulceration.

Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features.

FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.

P304

1883-92

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1309788

http://www.w3.org/2001/XMLSchema#string

P356

10.2217/FON.13.141

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259112717

http://www.w3.org/2001/XMLSchema#string

P698

24295418

http://www.w3.org/2001/XMLSchema#string